Objectives: Adults with RA are being switched from etanercept originator to biosimilar in non-medical/cost-saving switching. This analysis aims to investigate outcomes in these patients, including (i) drug survival and (ii) disease activity at 6 months and 12 months, compared with those who remain on the originator.
Methods: Using BSRBR-RA, those who switched directly from etanercept originator to biosimilar were identified and matched to patients receiving the originator, based on gender, age, disease duration and originator start year. Drug survival was calculated; Cox-proportional hazard models assessed differences in drug persistence between those who switched vs remaining on originator. Change in DAS28 after 6 months and 12 months was compared between cohorts. Multiple imputation was used.
Results: A total of 1024 adults with RA switching from etanercept originator to biosimilar were included, with a matched cohort of patients remaining on the originator. Patients who switched onto a biosimilar product were no more likely to discontinue etanercept treatment vs those who remained on the originator; hazard ratio 1.06 (95%CI 0.89-1.26), with 65% of patients remaining on treatment at three years. Ninety-five (9%) patients switched back to the originator within the first year. After 6 months and 12 months, biosimilar patients were no more likely to have a worsening of DAS28 (>0.6 units) compared with those who remained on the originator.
Conclusions: This is the largest matched comparative effectiveness analysis showing patients switching from etanercept originator to biosimilar appearing to do just as well with regard to disease activity and drug persistence compared with those who remained on the originator. These data will be reassuring to clinicians and patients regarding non-medical switching.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292141 | PMC |
| http://dx.doi.org/10.1093/rheumatology/kead470 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024.
Arch Dermatol Res
November 2024
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Article Synopsis
- - Psoriasis is a long-term inflammatory skin condition linked to T-lymphocyte activation, and treating it in individuals with HIV is challenging due to immune system complications.
- - This study reviewed 19 articles involving 24 cases of psoriasis in people with HIV, analyzing various therapies like apremilast and ustekinumab, which showed effectiveness in reducing skin symptoms and even some cases of psoriatic arthritis.
- - Although adverse events were rare and manageable, more comprehensive research is needed to clearly understand the safety and efficacy of these treatments for HIV-positive patients.
The role of neutrophils in pain: systematic review and meta-analysis of animal studies.
Pain
October 2024
Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain.
The peripheral inflammatory response is an attractive therapeutic target for pain treatment. Neutrophils are the first circulating inflammatory cells recruited to sites of injury, but their contribution to pain outcomes is unclear. We performed a systematic review and meta-analysis of original preclinical studies, which evaluated the effect of preemptive neutrophil depletion on pain outcomes (PROSPERO registration number: CRD42022364004).
View Article and Find Full Text PDFDrug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study.
Glob Reg Health Technol Assess
October 2024
Pescara General Hospital, Pescara - Italy.
Article Synopsis
- The study evaluates the use of biologic and targeted synthetic drugs for treating psoriatic arthritis (PsA) in Italy, specifically focusing on the role of biosimilar drugs.
- Conducted over four years at eight hospital pharmacies, the research tracked patients new to treatment, assessing their persistence and adherence to medication using the proportion of days covered (PDC).
- Findings revealed that patients on biosimilars showed better adherence and persistence than those on originators, and utilizing biosimilars resulted in significant cost savings, highlighting their potential benefits in healthcare resource optimization.
Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism.
Clin Exp Rheumatol
September 2024
Department of Rheumatology & CIC-CRB 1404, Rouen University, CHU de Rouen, France.
Article Synopsis
- * Conducted in France from 2018 to 2022, the study found that 13.1% of the 183 patients experienced a NE, with adverse events (AEs) like rheumatism reactivation being the most common.
- * The results suggest that a careful, practitioner-supervised transition to biosimilars can lower the risk of NE, highlighting the importance of shared medical decision-making for effective patient outcomes.
Background: Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments. Using Canadian administrative health data from 2015-2019, we compared the incidence of serious infection between biosimilars and bio-originators initiators for etanercept and infliximab, two of the most commonly used biologics during this time.
Methods: We performed a retrospective cohort study using pan-Canadian data (except Quebec) from the National Prescription Drug Utilization Information System linked to hospitalization data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!